考虑将重组带状疱疹疫苗用于脆弱儿科患者:一个新机会
该研究回顾了2018年1月至2023年5月一家三级儿科医院的VZV/HZ出院编码和阳性分子检测,纳入48例VZV患者和96例对照。48例中10例水痘、38例带状疱疹,36/48未接种疫苗,20/48有免疫相关合并症;完全接种在对照组更常见(43/96 vs 2/48,p<0.001)。作者认为若被证实安全有效,重组HZ疫苗或可为不适合减毒活疫苗的免疫受损儿童提供预防选择。
要点
- 48例VZV患者中38例为带状疱疹,36/48(75%)未接种疫苗,仅2/48(4.2%)完成两剂接种。
- 20/48(42%)有免疫相关合并症,合并症强烈预测带状疱疹住院(OR 4.71;95%CI 1.23-20.39;p=0.028)。
- 完全接种比例对照组43/96(45%)高于病例组2/48(4.2%)(p<0.001)。
核心结论
- 在本队列中,许多病例存在禁忌减毒活疫苗的合并症;若被证实安全有效,重组带状疱疹疫苗或可为不适合活病毒疫苗的免疫受损儿童提供预防选择。
研究设计与样本
- 回顾性分析2018年1月至2023年5月Meyer儿童医院的VZV/HZ出院编码和阳性VZV分子检测,纳入48例VZV患者,并按接种状态分为未接种、部分接种(单剂)和完全接种(完整两剂方案)。
- 同期纳入来自相同科室和时段的96例对照以评估VZV疫苗有效性。
主要发现
- 48例VZV患者中52%为女性,中位年龄11.6岁(IQR 7-14.2),10例为水痘、38例为带状疱疹。
- 48例中2/48(4.2%)接种2剂疫苗,10/48(20.8%)接种1剂,36/48(75%)未接种。
- 20/48(42%)存在免疫相关合并症;在因带状疱疹需住院的患者中,合并症强烈预测入院(OR 4.71;95%CI 1.23-20.39;p=0.028)。
- 完全接种在对照组43/96(45%)中比病例组2/48(4.2%)更常见(p<0.001)。
临床怎么用
- 作者认为,若被证实安全有效,重组带状疱疹疫苗或可为不适合减毒活疫苗的免疫受损儿童提供预防选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A recombinant vaccine is approved to prevent herpes zoster (HZ) in adults ≥50 years and immunocompromised individuals ≥19 years. However, in children, the live attenuated vaccine remains the only prevention strategy against varicella zoster virus (VZV), with only one trial evaluating the safety and immunogenicity of GlaxoSmithKline's HZ subunit candidate vaccine in immunocompromised children. OBJECTIVES: To estimate VZV burden in our third level pediatric hospital and identify high-risk pediatric groups for its occurrence and complications to explore the need for an inactivated vaccine. METHODS: We reviewed VZV/HZ hospital discharge codes and positive VZV molecular tests at Meyer Children's Hospital from January 2018 to May 2023. We categorized patients based on their vaccination status as unvaccinated, partially vaccinated (single dose), or fully vaccinated (complete two-dose regimen). 96 controls from the same Departments and period were also included to assess VZV vaccine effectiveness. RESULTS: Of 48 patients with VZV (52 % female; median age: 11.6 years [IQR: 7-14.2]), 10 had chickenpox and 38 HZ; 2/48 (4.2 %) received 2 doses of vaccination, 10/48 (20.8 %) were immunized with 1 dose and 36/48 (75 %) were unvaccinated. Immune-related comorbidities were present in 20/48 (42 %) patients, and among those with HZ requiring hospitalization, comorbidities strongly predicted admission (OR 4.71; 95 % CI, 1.23-20.39; p = 0.028). Full vaccination was more frequent in controls (43/96, 45 %) than in cases (2/48, 4.2 %; p < 0.001). CONCLUSIONS: In our cohort, many cases had comorbidities contraindicating the live attenuated vaccine. If proven safe and effective, the recombinant HZ vaccine could offer a preventive option for immunocompromised children ineligible for live viral vaccines.
引用
- Mollo A, Peri M, Lodi L, et al. Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity. Vaccine. 2025. PMID: 40198934. doi:10.1016/j.vaccine.2025.127072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。